Serous Cystadenoma

A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)

Also Known As:

Networked: 189 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Cysts
2.	Pathologic Constriction (Stenosis)
3.	Neoplasms (Cancer)
4.	Mucinous Cystadenoma
5.	Adenocarcinoma

Experts

1.	Klimstra, David S: 5 articles (10/2012 - 02/2006)
2.	Brustmann, Hermann: 5 articles (07/2008 - 01/2002)
3.	Andruss, Bernard F: 3 articles (11/2014 - 09/2012)
4.	Szafranska-Schwarzbach, Anna E: 3 articles (11/2014 - 09/2012)
5.	Traiman, Paulo: 3 articles (05/2014 - 08/2012)
6.	Braga, Letícia da Conceição: 3 articles (05/2014 - 08/2012)
7.	Silva, Luciana Maria: 3 articles (05/2014 - 08/2012)
8.	Hruban, Ralph H: 3 articles (09/2012 - 12/2011)
9.	Adsay, N Volkan: 3 articles (03/2011 - 02/2006)
10.	Lee, Linda S: 2 articles (11/2014 - 01/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Serous Cystadenoma:

1.	tranilast (N 5')IBA 10/01/2009 - "Most patients had a non-malignant lesion (n = 65, 83%) (mucinous cystadenoma (n = 29), serous cystadenoma (n = 15), IPMN without invasion (n = 8), pseudocyst (n = 8), other benign (n = 5)). " 10/01/2005 - "Final diagnoses included serous cystadenoma (SCA, n=5), islet cell tumor (n=2), mixed seromucinous lesion (n=1), polycystic disease of the pancreas (n=1), and pseudocyst (n=1). " 10/01/1996 - "The series of 51 surgical specimens included 18 serous cystadenomas, 20 mucinous cystic tumors (benign, n = 14; borderline, n = 1; malignant, n = 5), 10 intraductal papillary-mucinous tumors (benign, n = 4; borderline, n = 1; malignant, n = 5), and 3 papillary and cystic tumors. " 03/01/2015 - "These presented as single simple cysts (n = 5, 9.1%), multiple simple cysts (n = 14, 25.5%), serous cystadenoma (n = 29, 52.7%), or neuroendocrine tumors (NETs) (n = 17, 30.9%). " 05/01/2010 - "The most commonly resected tumors were intraductal papillary mucinous neoplasms (n = 9), serous cystadenomas (n = 5), and neuroendocrine tumors (n = 4). "
2.	ParaffinIBA 11/01/2014 - "Sixty-eight surgically resected formalin fixed, paraffin embedded pancreatic specimens were analyzed, including: 1) benign (20 serous cystadenoma (SCA)), 2) pre-malignant (10 mucinous cystic neoplasm (MCN), 10 branch duct intraductal papillary mucinous neoplasm (BD-IPMN), 9 main duct IPMN (MD-IPMN)), 3) malignant (19 PDAC). " 02/01/2009 - "Immunohistochemistry was performed to detect the expression of THY1 gene in formalin-fixed, paraffin-embedded specimens of normal ovaries (n = 25), ovarian serous cystadenoma (n = 25), and serous cystadenocarcinoma (n = 53). " 07/01/2012 - "Multiple tissue microarrays (TMA) were created from cores of formalin-fixed paraffin-embedded blocks containing pancreatic adenocarcinomas (n=112), neuroendocrine tumors (n=99), serous cystadenomas (n=28), and SPT (n=14) as well as normal pancreas (n=12). " 01/01/1992 - "Flow cytometric analysis of DNA content and ras p21 expression were studied in paraffin-embedded normal ovary (NO, n = 10), serous cystadenoma (SA, n = 11), serous tumors of low malignant potential (LMP, n = 13), and papillary serous cystadenocarcinoma (SCa, n = 7). " 01/01/1996 - "To establish a basis for the interpretation of DNA flow cytometric results of gynecologic neoplasms, paraffin blocks from 121 patients with a diagnosis of serous cystadenoma (n = 37), mucinous cystadenoma (n = 28), leiomyoma (n = 41), and fibrothecoma (n = 15), and normal tissue samples obtained from some of these patients, including ovary (n = 20), cervix (n = 20), and myometrium (n = 20) were analyzed for nuclear DNA content. "
3.	Formaldehyde (Formol)FDA Link 11/01/2014 - "Sixty-eight surgically resected formalin fixed, paraffin embedded pancreatic specimens were analyzed, including: 1) benign (20 serous cystadenoma (SCA)), 2) pre-malignant (10 mucinous cystic neoplasm (MCN), 10 branch duct intraductal papillary mucinous neoplasm (BD-IPMN), 9 main duct IPMN (MD-IPMN)), 3) malignant (19 PDAC). " 02/01/2009 - "Immunohistochemistry was performed to detect the expression of THY1 gene in formalin-fixed, paraffin-embedded specimens of normal ovaries (n = 25), ovarian serous cystadenoma (n = 25), and serous cystadenocarcinoma (n = 53). " 07/01/2012 - "Multiple tissue microarrays (TMA) were created from cores of formalin-fixed paraffin-embedded blocks containing pancreatic adenocarcinomas (n=112), neuroendocrine tumors (n=99), serous cystadenomas (n=28), and SPT (n=14) as well as normal pancreas (n=12). " 04/01/2009 - "The study was performed on formalin-fixed, paraffin-embedded tissue samples from 75 epithelial ovarian tumors, 15 serous cystadenomas, 15 mucinous cystadenomas, 5 borderline serous cystadenomas, 5 borderline mucinous cystadenomas, 15 serous cystadenocarcinomas, 15 mucinous cystadenocarcinomas and 5 endometrioid carcinomas. " 09/01/2005 - "Formalin-fixed, paraffin-embedded archival tissue sections of 10 benign serous cystadenomas, 10 serous neoplasms of low malignant potential (LMP), and 41 serous ovarian carcinomas were immunostained with antibodies to hTERT and c-kit. "
4.	Messenger RNA (mRNA)IBA 03/05/2013 - "And the mRNA expressions of GRP78 in normal ovarian tissue, ovarian serous cystadenoma and ovarian serous cystadenocarcinoma were 0.134 ± 0.021, 0.121 ± 0.032 and 0.685 ± 0.085 respectively. " 05/01/1996 - "In situ hybridization gave negative results for glycodelin mRNA in normal ovary, whereas in ovarian tumors strong expression of both the glycodelin mRNA and the protein were found in benign and malignant serous cystadenomas, mucinous ovarian tumors being negative. " 02/01/2004 - "Epithelial telomerase reverse transcriptase mRNA expression was detected in 28 of 31 epithelial ovarian carcinomas, 1 of 1 malignant granulosa cell tumor, 7 of 9 serous borderline ovarian tumors, 11 of 11 mucinous borderline ovarian tumors, 4 of 5 serous cystadenofibromas, 2 of 4 serous cystadenomas, 8 of 8 mucinous cystadenomas, and 0 of 6 normal ovaries except the corpus luteum. " 07/01/1997 - "The present study analyzes and compares the expression of its precursor beta 1-latency-associated peptide (beta 1-LAP), its latent binding protein (LTBP), and its mRNA in ductal adenocarcinoma (n = 10), in IPMN (n = 8), in serous cystadenoma (n = 2), and in normal tissues (n = 5). "
5.	Chemokine CCL5IBA 01/01/2011 - "This study was undertaken to evaluate RANTES levels in the peritoneal fluid (PF) and plasma of patients with ovarian cancer (n=73), serous cystadenoma (n=32) or normal controls (n=9). "
6.	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/01/2000 - "The present study evaluated the concentrations of inhibin A and inhibin B and the relationship with oestradiol and nitric oxide metabolites in fluid collected from benign ovarian serous cystadenomas (n = 15). " 12/01/2000 - "High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites."
7.	MetallothioneinIBA 07/01/2009 - "The objective of this study was to determine the expression levels of metallothionein (MT) and p53 protein, recognized neoplastic transformation markers, in pancreatic serous cystadenomas (SCA) and adenomocarcinomas. " 07/01/2009 - "Immunohistochemical localization of metallothionein and p53 protein in pancreatic serous cystadenomas."
8.	Estradiol (Estrace)FDA LinkGeneric 12/01/2000 - "The present study evaluated the concentrations of inhibin A and inhibin B and the relationship with oestradiol and nitric oxide metabolites in fluid collected from benign ovarian serous cystadenomas (n = 15). " 12/01/2000 - "High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites."
9.	Carrier Proteins (Binding Protein)IBA 07/01/1997 - "The present study analyzes and compares the expression of its precursor beta 1-latency-associated peptide (beta 1-LAP), its latent binding protein (LTBP), and its mRNA in ductal adenocarcinoma (n = 10), in IPMN (n = 8), in serous cystadenoma (n = 2), and in normal tissues (n = 5). "
10.	inhibin BIBA 12/01/2000 - "High concentrations of inhibin A (median = 89.3 ng/ml) and inhibin B (median = 116.1 ng/ml) were found in the cystic fluid of ovarian serous cystadenomas. " 12/01/2000 - "The present study evaluated the concentrations of inhibin A and inhibin B and the relationship with oestradiol and nitric oxide metabolites in fluid collected from benign ovarian serous cystadenomas (n = 15). " 12/01/2000 - "High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites."

Therapies and Procedures

1.	Choledochostomy 01/01/2006 - "We made a preoperative diagnosis of macrocystic serous cystadenoma (SCA) of the pancreas, but did not perform palliative choledochojejunostomy because aspiration of the pancreatic cystic fluid caused the cysts to shrink and relieved the compressive stenosis of the common bile duct (CBD) during the operation. "
2.	Drug Therapy (Chemotherapy) 09/01/1989 - "In the present study, a 22-year-old, nulliparous woman was presented, who had had her right ovary extirpated for serous cystadenoma (low potential for malignancy) and had undergone chemotherapy previously. "
3.	Pancreatectomy 06/01/2009 - "A distal pancreatectomy was performed, and histologic examination confirmed a serous cystadenoma of the pancreas. " 05/01/2008 - "Subtotal pancreatectomy was performed for multiple serous cystadenoma. " 06/01/2006 - "Laparoscopic distal pancreatectomy with splenic preservation for serous cystadenoma: a case report and literature review." 05/01/2005 - "Both patients underwent laparoscopic distal pancreatectomy with splenic conservation for an oligocystic serous cystadenoma and serous cystadenoma. " 03/01/2004 - "distal pancreatectomy or pancreaticoduodencetomy in patients with serous cystadenoma of the pancreas. "
4.	Pancreaticoduodenectomy 04/01/2015 - "We performed subtotal stomach-preserving pancreaticoduodenectomy, and histopathological diagnosis was serous cystadenoma. " 04/01/2000 - "For a symptomatic serous cystadenoma, duodenum-preserving pancreatic head resection is a good alternative to partial duodenopancreatectomy. " 01/01/2003 - "Although serous cystadenoma of the pancreas has essentially a benign nature, pylorus-preserving pancreatoduodenectomy is the treatment of choice when available to avoid the recurrence of obstructive jaundice." 01/01/2003 - "With a preoperative diagnosis of pancreatic serous cystadenoma with obstructive jaundice, he underwent pylorus-preserving pancreatoduodenectomy. " 07/01/2008 - "Following clinical and paraclinical evaluation, patients with serous cystadenomas received distal pancreatectomy and splenectomy, and MCNs patients received cephalic duodenopancreatectomy (3 cases), distal pancreatectomy and splenectomy (3 cases), segmental corporeo-caudal pancreatectomy (1 case) and choledocoduodenostomy and gastrojejunostomy (1 case). "
5.	Splenectomy 08/14/2015 - "A serous cystadenoma or pseudocyst of the pancreas was initially suspected, and the patient underwent a subtotal pancreatectomy and splenectomy. " 01/01/2012 - "The patient underwent a distal pancreatectomy and splenectomy; the pathology report demonstrated a giant serous cystadenoma of the body and tail of the pancreas. " 07/01/2001 - "After the diagnosis of serous cystadenoma of the pancreas, the patient underwent distal pancreatectomy and splenectomy. " 10/01/1998 - "Preoperatively, the cystic lesion of the pancreas was diagnosed as a serous cystadenoma and subsequently the patient, a 71-yr-old woman, underwent distal pancreatectomy with splenectomy. " 07/01/2008 - "Following clinical and paraclinical evaluation, patients with serous cystadenomas received distal pancreatectomy and splenectomy, and MCNs patients received cephalic duodenopancreatectomy (3 cases), distal pancreatectomy and splenectomy (3 cases), segmental corporeo-caudal pancreatectomy (1 case) and choledocoduodenostomy and gastrojejunostomy (1 case). "